Search Results - "Vallejo, Adrián"
-
1
Accurate prediction of kinase-substrate networks using knowledge graphs
Published in PLoS computational biology (03-12-2020)“…Phosphorylation of specific substrates by protein kinases is a key control mechanism for vital cell-fate decisions and other cellular processes. However,…”
Get full text
Journal Article -
2
FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted
Published in Journal of hepatology (01-08-2021)“…Cholangiocarcinoma (CCA) is a neoplasia of the biliary tract driven by genetic, epigenetic and transcriptional mechanisms. Herein, we investigated the role of…”
Get full text
Journal Article -
3
An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer
Published in Nature communications (21-02-2017)“…KRAS mutated tumours represent a large fraction of human cancers, but the vast majority remains refractory to current clinical therapies. Thus, a deeper…”
Get full text
Journal Article -
4
Chronic kidney disease promotes cerebral microhemorrhage formation
Published in Journal of neuroinflammation (25-02-2023)“…Chronic kidney disease (CKD) is increasingly recognized as a stroke risk factor, but its exact relationship with cerebrovascular disease is not…”
Get full text
Journal Article -
5
The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer
Published in Molecular cancer (20-05-2023)“…The discovery of functionally relevant KRAS effectors in lung and pancreatic ductal adenocarcinoma (LUAD and PDAC) may yield novel molecular targets or…”
Get full text
Journal Article -
6
Inhibitor of differentiation-1 (Id1) sustains mutant KRAS-driven progression, maintenance, and metastasis of lung adenocarcinoma via regulation of a FOSL1 network
Published in Cancer research (Chicago, Ill.) (01-02-2019)“…Due to the refractory nature of mutant KRAS lung adenocarcinoma (LUAD) to current therapies, identification of new molecular targets is essential. Genes with a…”
Get full text
Journal Article -
7
Correction: The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer
Published in Molecular cancer (16-06-2023)Get full text
Journal Article -
8
Genetic Mouse Models as In Vivo Tools for Cholangiocarcinoma Research
Published in Cancers (26-11-2019)“…Cholangiocarcinoma (CCA) is a genetically and histologically complex disease with a highly dismal prognosis. A deeper understanding of the underlying cellular…”
Get full text
Journal Article -
9
All for one and FOSL1 for all: FOSL1 at the crossroads of lung and pancreatic cancer driven by mutant KRAS
Published in Molecular & cellular oncology (04-05-2017)“…KRAS proto-oncogene, GTPase (KRAS) remains refractory to current therapies. We devised an integrative cross-tumor approach to expose common core elements…”
Get full text
Journal Article -
10
Analysis of Common Exercise Modalities in Improving Athletic Performance in Older Adults: A Narrative Review
Published in Current sports medicine reports (01-06-2024)“…Exercise leads to robust cardiovascular, musculoskeletal, and psychological benefits that improve quality of life and longevity for older adults, but…”
Get full text
Journal Article -
11
Abstract TP127: Hypertension Provokes Development Of Cerebral Microhemorrhages In A Mouse Model
Published in Stroke (1970) (01-02-2022)“…IntroductionCerebral microhemorrhages (CMH) are the pathological substrate for cerebral microbleeds, represent focal hemosiderin deposits on MRI, and are…”
Get full text
Journal Article -
12
Abstract 87: Chronic Kidney Disease Induces Cerebral Microhemorrhages In Aged Mice
Published in Stroke (1970) (01-02-2022)“…IntroductionChronic kidney disease (CKD) is increasingly recognized as a risk factor of cerebral microvascular disease, but its association with common…”
Get full text
Journal Article -
13
The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas
Published in The Journal of clinical investigation (01-04-2020)“…Few therapies are currently available for patients with KRAS-driven cancers, highlighting the need to identify new molecular targets that modulate central…”
Get full text
Journal Article